Selecting Hypoxic Tumours for Treatment Modification

Recruiting Observational Study
Bladder (Urothelial, Transitional Cell) Cancer Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
30 (estimated)
Sponsor
University of Manchester · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (\>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxic tumours have a poor prognosis. This can be improved with treatment intensification. Treatment intensification can be modification with CON (breathing O2-enriched air + oral administration of nicoti…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: This will be tumour site dependent. Bladder: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Cervix: * Older than age 18 years. * Patients having radiother…
Contacts

Rachel Reed, MSc

01619184780

rachel.reed@manchester.ac.uk

CONTACT

Kimberley Reeves, PhD

01619184780

kimberley.reeves@manchester.ac.uk

CONTACT